Literature DB >> 17428932

Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.

A Espinel-Ingroff1, B Arthington-Skaggs, N Iqbal, D Ellis, M A Pfaller, S Messer, M Rinaldi, A Fothergill, D L Gibbs, A Wang.   

Abstract

The purpose of this study was to correlate inhibition zone diameters, in millimeters (agar diffusion disk method), with the broth dilution MICs or minimum effective concentrations (MECs) (CLSI M38-A method) of five antifungal agents to identify optimal testing guidelines for disk mold testing. The following disk diffusion testing parameters were evaluated for 555 isolates of the molds Absidia corymbifera, Aspergillus sp. (five species), Alternaria sp., Bipolaris spicifera, Fusarium sp. (three species), Mucor sp. (two species), Paecilomyces lilacinus, Rhizopus sp. (two species), and Scedosporium sp. (two species): (i) two media (supplemented Mueller-Hinton agar [2% dextrose and 0.5 microg/ml methylene blue] and plain Mueller-Hinton [MH] agar), (ii) three incubation times (16 to 24, 48, and 72 h), and (iii) seven disks (amphotericin B and itraconazole 10-microg disks, voriconazole 1- and 10-microg disks, two sources of caspofungin 5-microg disks [BBL and Oxoid], and posaconazole 5-microg disks). MH agar supported better growth of all of the species tested (24 to 48 h). The reproducibility of zone diameters and their correlation with either MICs or MECs (caspofungin) were superior on MH agar (91 to 100% versus 82 to 100%; R, 0.71 to 0.93 versus 0.53 to 0.96 for four of the five agents). Based on these results, the optimal testing conditions for mold disk diffusion testing were (i) plain MH agar; (ii) incubation times of 16 to 24 h (zygomycetes), 24 h (Aspergillus fumigatus, A. flavus, and A. niger), and 48 h (other species); and (iii) the posaconazole 5-microg disk, voriconazole 1-microg disk, itraconazole 10-microg disk (for all except zygomycetes), BBL caspofungin 5-microg disk, and amphotericin B 10-microg (zygomycetes only).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428932      PMCID: PMC1933077          DOI: 10.1128/JCM.00134-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates.

Authors:  Sevtap Arikan; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

4.  Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

5.  Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A Fothergill; M Ghannoum; E Manavathu; L Ostrosky-Zeichner; M Pfaller; M Rinaldi; W Schell; T Walsh
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method.

Authors:  E López-Oviedo; A I Aller; C Martín; C Castro; M Ramirez; J M Pemán; E Cantón; C Almeida; E Martín-Mazuelos
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

8.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

9.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 10.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

View more
  33 in total

Review 1.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; E Canton
Journal:  J Clin Microbiol       Date:  2008-03-12       Impact factor: 5.948

3.  In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.

Authors:  Cornelia Lass-Flörl; Ana Alastruey-Izquierdo; Manuel Cuenca-Estrella; Susanne Perkhofer; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

4.  Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi.

Authors:  Carmelo Massimo Maida; Maria Eleonora Milici; Laura Trovato; Salvatore Oliveri; Emanuele Amodio; Elisabetta Spreghini; Giorgio Scalise; Francesco Barchiesi
Journal:  J Clin Microbiol       Date:  2008-10-15       Impact factor: 5.948

5.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

6.  Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital.

Authors:  L X Bonfietti; M W Szeszs; M R Chang; M A Martins; S R B S Pukinskas; M O Nunes; G H Pereira; A M M Paniago; S U Purisco; M S C Melhem
Journal:  Mycopathologia       Date:  2012-07-21       Impact factor: 2.574

7.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

Review 8.  Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.

Authors:  Anna Dudakova; Birgit Spiess; Marut Tangwattanachuleeporn; Christoph Sasse; Dieter Buchheidt; Michael Weig; Uwe Groß; Oliver Bader
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

9.  Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

Authors:  R Araujo; S Costa-de-Oliveira; I Coutinho; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

10.  New insight into amphotericin B resistance in Aspergillus terreus.

Authors:  Gerhard Blum; Caroline Hörtnagl; Emina Jukic; Thomas Erbeznik; Thomas Pümpel; Hermann Dietrich; Markus Nagl; Cornelia Speth; Günter Rambach; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.